Regulation of food intake by gastrointestinal hormones

Current Opinion in Gastroenterology

Volumn 22, Issue 6, 2006, Pages 626-631

  Baynes, Kevin C R ^a   Dhillo, Waljit S ^a   Bloom, Stephen R ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Ghrelin; Glucagon like peptide 1; Obesity; Oxyntomodulin; Peptide YY 3 36

Indexed keywords

ANTIOBESITY AGENT; EXENDIN 4; GASTROINTESTINAL HORMONE; GASTROINTESTINAL POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; OBESTATIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PROGLUCAGON; UNCLASSIFIED DRUG;

ANOREXIA; APPETITE; BODY WEIGHT; CACHEXIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; ENDOCRINE CELL; FOOD INTAKE; HUMAN; INTESTINE CELL; INTESTINE MOTILITY; INTESTINE SECRETION; MEDICAL RESEARCH; NAUSEA AND VOMITING; NONHUMAN; OBESITY; PANCREAS CELL; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; STARVATION; STOMACH BYPASS; WEIGHT REDUCTION;

ANIMALS; APPETITE REGULATION; GASTROINTESTINAL HORMONES; HUMANS; OBESITY;

EID: 33750289553     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000245537.43142.63     Document Type: Review

References (53)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404:635-643.
2. Friedman JM. Modern science versus the stigma of obesity. Nat Med 2004; 10:563-569.
3. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116:337-350.
4. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
5. Ghigo E, Broglio F, Arvat E, et al. Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol 2005; 62:1-17. A comprehensive review of multiple aspects of ghrelin physiology and biochemistry.
6. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141:4325-4328.
7. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992-5995.
8. Tschöp M, Smiley D, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407:908-913.
9. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005; 128:1187-1193. Demonstration that ghrelin administration may increase body weight in underweight humans.
10. Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005; 16:2111-2118.
11. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:2832-2836.
12. Miljic D, Pekic S, Djurovic M, et al. Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa. J Clin Endocrinol Metab 2006; 91:1491-1495.
13. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23:7973-7981.
14. Sun Y, Wang P, Zheng H, et al. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 2004; 101:4679-4684.
15. Wortley KE, del Rincon JP, Murray JD, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005; 115:3573-3578. Phenotype different from that reported by Sun et al. [13].
16. Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005; 115:3564-3572. Study conditions may affect the observed phenotype in knockout mouse models.
17. Shearman LP, Wang S-P, Helmling S, et al. Ghrelin neutralization by an RNA-Spiegelmer ameliorates obesity in diet-induced obese mice. Endocrinology 2005; 147:1517-1526. Novel technique for studying physiology in vivo.
18. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714-1719.
19. Drazen DL, Vahl TP, D'Alessio DA, et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology 2006; 147:23-30. Suggests that ghrelin has complex effects on feeding behaviour.
20. English PJ, Ghatei MA, Malik IA, et al. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002; 87:2984-2987.
21. Le Roux CW, Patterson M, Vincent RP, et al. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 2005; 90:1068-1071. Do obese people have a primary defect in their satiety mechanisms or is this a secondary phenomenon?
22. Zhang JV, Ren P-G, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310:996-999. A newly described gut peptide with effects on appetite.
23. 3-36 physiologically inhibits food intake. Nature 2002; 418:650-654.
24. 3-36 decrease food intake in rodents? Nature 2004; 430:1-3.
25. Challis BG, Pinnock SB, Coll AP, et al. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 2003; 311:915-919.
26. Pittner RA, Moore CX, Bhavsar SP, et al. Effects of PYY (3-36) in rodent models of diabetes and obesity. Int J Obes 2004; 28:963-971.
27. (3-36) potently inhibits food intake in rats. Endocrinology 2005; 146:879-888.
28. Moran TH, Smedh U, Kinzig KP, et al. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 2005; 288:R384-R388.
29. Koegler FH, Enriori PJ, Billes SK, et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in Rhesus macaques. Diabetes 2005; 54:3198-3204.
30. Abbott CR, Small CJ, Sajedi A, et al. The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat. Int J Obes 2006; 30:288-292. Methodological paper exploring the difficulty in investigating feeding behaviour in rodents.
31. 3-36 on food intake in humans. Gastroenterology 2005; 129:1430-1436.
32. 3-36. N Engl J Med 2003; 349:941-948.
33. Schonhoff S, Baggio L, Ratineau C, et al. Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol Cell Biol 2005; 25:4189-4199.
34. Boey D, Lin S, Karl T, et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006; 49:1360-1370.
35. 3-36.
36. Adrian T, Savage A, Bacarese-Hamilton A, et al. Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 1986; 2:379-384.
37. 3-36 in obese subjects contribute to the maintenance of their obese phenotype?
38. Young AA. Obesity: A peptide YY-deficient, but not peptide YY-resistant, state. Endocrinology 2006; 147:1-2.
39. Batterham RL, Le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88:3989-3992.
40. Schmidt PT, Naslund E, Gryback P, et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 2005; 90:5241-5246.
41. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2006; 1:22-31. An authoritative review covering GLP-1, GLP-2 and dipeptidyl-peptidase-IV.
42. 3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem- hypothalamic pathway. Brain Res 2005; 1044:127-131. Demonstration that gut peptides have more than one site of action.
43. Heine RJ, van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143:559-569.
44. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27:1335-1342.
45. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-1100.
46. 3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146:3748-3756. Suggests that different gut peptides have complementary actions rather than redundancy.
47. 7-36 inhibit food intake additively. Endocrinology 2005; 146:5120-5127.
48. Dakin CL, Small CJ, Batterham RL, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145:2687-2695.
49. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88:4696-4701.
50. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54:2390-2395. Proof of concept study that oxyntomodulin reduces both food intake and weight in humans.
51. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes 2006 (epub ahead of print) Gut hormones may affect behaviours other than food intake.
52. Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005; 128:175-191. Balanced review covering metabolic aspects of bariatric surgery.
53. Le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243:108-114. The mechanism of weight loss following bariatric surgery may include alteration of gut peptide release.